Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers
- 25 Downloads
The debrisoquine/sparteine-type polymorphism of drug oxidation and the polymorphism for acetylation are two common inherited variations in human drug metabolism. The phenotypes for hydroxylation and acetylation can be predicted be newly developed methods based on mutation-specific amplification of DNA by the polymerase chain reaction (PCR), which also allow for identification of heterozygous carriers of one mutant allele.
In the present study, the results of genotyping of 81 healthy European volunteers were compared with the phenotype obtained by the classical biochemical approach using debrisoquine and caffeine as probe drugs.
Genotyping correctly predicted all 73 extensive metabolisers (EMs) and 6 out of 8 poor metabolisers (PMs) of debrisoquine. All 48 rapid acetylators and 33 of 35 slow acetylators were predicted.
Overall, the DNA analysis result matched the in vivo phenotype in 97.5 % of individuals.
Key wordsDebrisoquine, Polymerase chain reaction pharmacogenetics, genotype-phenotype, caffeine
restriction fragment length polymorphism
polymerase chain reaction
- D6-A, D6-B, D6-C, D6-D
defined mutations of the CYP2D6 gene
- M1, M2, M3
defined mutations of the NAT2 gene
Unable to display preview. Download preview PDF.
- 1.Mahgoub A, Idle J, Dring LG, Lancester R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584–586Google Scholar
- 2.Eichelbaum M, Spannbrucker N, Dengler HJ (1975a) N-oxidation of sparteine in man and its interindividual differences. Arch Pharmacol 187: R 94Google Scholar
- 4.Knight RA, Selin MJ, Harris HW (1959) Genetic factors influencing isoniazid blood levels in humans. Veterans Administration 18th Conference of Chemotherapy of Tuberculosis. V A. Department of Medicine and Surgery Central Office, Washington D. C., p 52Google Scholar
- 5.Evans DAP, Manley KA, McKusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 2: 485–491Google Scholar
- 6.Meyer UA, Zanger UM, Grant D, Blum D (1990) Genetic polymorphisms of drug metabolism. Adv Drug Res 19: 197–241Google Scholar
- 11.Evans DAP (1989) N-acetyltransferase. Pharmac Ther 42: 157–234Google Scholar
- 15.Cano JP, Berger Y, Fabre G, von Bahr C, Case DE, Gundert-Remy U, Rane A (1990) Relevance of genetic polymorphisms of metabolism for drug development. In: Alvan G, Balant LP, Bechtel PR, Boobis AR, Gram LF, Pithan K (eds) European cooperation in the field of scientific and technical research: European consensus conference on pharmacogenetics. Office for official publication of the European communities, Luxembourg, pp 113–145Google Scholar
- 18.Meyer UA, Skoda RC, Zanger UM (1990) The genetic polymorphism of debrisoquine/sparteine metabolism — molecular mechanisms. Pharmac Ther 46: 297–308Google Scholar
- 19.Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265: 17209–17214PubMedGoogle Scholar
- 28.Nei M (1987) Molecular evolutionary genetics. Columbia University Press, New YorkGoogle Scholar